ECONOMICAL ANALYSIS OF SUBCUTANEOUS VERSUS INTRAVENOUS TRASTUZUMAB


Puerto Real University Hospital, Cádiz, Spain.

PURPOSE
To assess the cost minimization achieved by using
Subcutaneous trastuzumab (600mg/21 days)
Intravenous trastuzumab (various dosifications)
For treatment of HER2+ breast cancer

MATERIAL AND METHODS

January 1st 2015 to September 30th 2015

Body weight calculated

Diferent protocols for intravenous trastuzumab
Comparable to
• 6 mg/kg/21 days
Subcutaneous trastuzumab
Fixed dose
• 600 mg/21 days

The cost for each patient was calculated according to sc and iv dosifications and the number of administrations received

RESULTS

Patients
312 administrations > 63kg patients

CONCLUSION

1. Two-thirds of patients who received trastuzumab weighted more than 63kg.
2. Few patients of this group received subcutaneous trastuzumab.
3. Most of the patients of the study received a treatment with a higher cost than the new form subcutaneous trastuzumab.